| :: ym biosciences |
YM BioSciences Inc. announced that it has been granted two additional patents in the US for AeroLEF®, the Company's proprietary,
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about YMI , Nov.
2012-01-08 YMI: Ym Biosciences Inc Institutional Investments! Ym Biosciences Inc sold some -239367 shares, change of -32.50% to total position of $879943
YM BioSciences Inc. (NYSE: YMI), (TSX: YM), a drug development Fiscal 2011, YM's majority-owned joint venture, CIMYM BioSciences Inc.
Hoovers company profile of YM BioSciences Inc.. Find detailed business information such as key executives, financials and other corporate data on YM
Drug developer YM BioSciences Inc. (AMEX:YMI) (TSX:YM.TO) posted a narrower loss for the first quarter compared with the comparable
Students will learn: The strategic factors that enter into an acquisition, How investment bankers place a value on a life sciences company by
MISSISSAUGA, Canada I December 12, 2011 I M BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported updated results from the
YM BioSciences' detailed financials; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry
YM BioSciences Inc. (AMEX:YMI) is up 10.96% in midday trading at $1.62. YMI has traded 5.6 million shares so far today, 5 times its daily
Forum - YM BioSciences - YMI 3364, YM BioSciences (YMI) Not Aware of Any Reason Behind Unusual Stock Movement, -, Leoncina, 11/22/2011 14:54
YM BioSciences to Report Updated Phase I/II Data for CYT387 at ASH 2011 Nov 07, YM Biosciences management to meet with Collins Stewart Nov 04, 2011
Ym Biosciences is located at 701 Lee Rd Ste 200 Chesterbrook, PA. Phone: 610- 560-0600. . Post a message and leave a review for Ym Biosciences.
Shares of YM BioSciences Inc. opened at 2.01 on Thursday. YM BioSciences Inc. has a 52 week low of $1.24 and a 52 week high of $3.78.
YM BioSciences Inc. YMI (ASE). AD: Find a Broker; Help. Real-time prices for U.S.-listed stocks, including premarket and after hours, reflect trading through
MISSISSAUGA, ON, Nov. 7, 2011 /PRNewswire via COMTEX/ -- YM BioSciences Inc. /quotes/zigman/23376/quotes/nls/ymi YMI +3.80%
7, 2011 /PRNewswire/ - YM Biosciences Inc . (NYSE Amex: YMI, TSX: YM), today announced it would report updated results from its Phase I/II
YM BioSciences Inc. Company Profile - View the latest news, market research, credit research, and investment research on YM BioSciences Inc. Mississauga
Six leading academic centers in the U.S. and Canada to recruit 60 patients into JAK1/JAK2 inhibitor twice-daily study - MISSISSAUGA, ON,
Do not invest in Ym Biosciences, Inc (YMI) stock before you read this free research report on the company.
YM BioSciences Inc.-Therapeutic Competitors Report YM BioSciences Inc.- Therapeutic Competitors Report Report includes a business
FE Investegate announcements from YM BioSciences Inc., YM BioSciences to present results of Norelin(TM
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM),
Diskussion zum Thema: 600% Kurspotential YM Biosciences 911799 - 14.03.06.
YM BioSciences is a product development company. Our focus is to advance cancer products along the regulatory and clinical pathways towards commercial
YM BioSciences (YMI) and Incyte (INCY). With all the hype Ym BioSciences reported data from their Phase 1-2 study of their drug CYT387.
Wall Street turned out in force Friday to examine YM BioSciences' experimental myelofibrosis drug at the American Society of Clinical Oncology
YM Biosciences Inc. stock price today: (YMI) stock quote, price history, earnings per share, technical analysis chart and breaking news.
YM BioSciences is a bio-pharmaceutical company which is evaluating lead compound nimotuzumab (nimo) (an IgG1, humanized epidermal
Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported - - Well tolerated for dosing periods up to
Following a management review of YM BioSciences 's two randomized, Phase II, double-blind trials of nimotuzumab in patients with brain
{The Medical News via BioPortfolio} YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and
Mississauga, Ontario, Canada - YM BioSciences Inc. ("YM" or the "Company"), the international cancer drug development company, today announces its
YMI - YM BioSciences Inc - SocialPicks. YM BioSciences (AMEX: YMI): Griffin Reiterates Buy Rating, Ups Price Target to $5.50 Graphic_rating_buy YMI
YM BioSciences Inc. (NYSE: YMI) today announced it has filed a preliminary short form base shelf prospectus with securities regulatory
YM BioSciences USA Inc. company research & investing information. Find executives and the latest company news.
Press Releases. © 2009 YM BioSciences Inc. privacy policy legal disclaimer
YM BioSciences Inc. is a drug development company advancing three clinical- stage products: CYT387, a small molecule, dual inhibitor of
YM BioSciences retains full global commercialization rights to CYT387. YM BioSciences Inc. is a drug development company advancing
YM BioSciences (YMI) announced preliminary results from a Phase 2 study of nimo in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC).
Stock quote for YM BioSciences, Inc. (YMI) - Get real-time last sale and extended hours stock prices, company news, charts, and
FE Investegate announcements from YM BioSciences Inc., Statement re YM BioSciences receives FDA fast t
YM Biosciences Rises on Promising Study Data for Blood Drug. 12/13/2011 by Minyanville. 3 Biotechs Making Big Moves on Big News
YM BIOSCIENCES AUSTRALIA MELBOURNE, Business profile, news and updates.
15 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and
YM BIOSCIENCES INC. SM CONTROLLED EQUITY OFFERING AMENDMENT NO. 1 TO THE SALES AGREEMENT.
YM BioSciences Inc. Message board - Online Community of active, educated investors researching and discussing YM BioSciences Inc. Stocks.
YM BioSciences Inc. (AMEX: YMI) is a drug development company. It is currently advancing three clinical stage products: CYT387, a small
Product profiles for late stage and clinical stage products of YM BioSciences with complete description of the product's developmental history,
Stock analysis for YM:CN. Get stock price, historical stock charts & news for YM Biosciences Inc, in the Therapeutics industry.
YM BioSciences (YMI) stock quote, charts, historical data, financials.
YM BioSciences Inc. (AMEX: YMI) Digging Deeper into the Bullish Sentiment and TooNiceStocks research has unveiled YM Biosciences Inc. has been the
YM BioSciences, a drug development company, has decided to terminate two randomized, Phase II, double-blind trials of nimotuzumab in
YM BioSciences Comments on Unusual Market Activity MISSISSAUGA, ON, Nov. 22, 2011 /CNW/ - YM BioSciences Inc. , today reported that,
YM BioSciences Inc.-Therapeutic Competitors Report Report includes a business summary, tabular representation of the number and percentage of products in
Dr. Nick Glover, Ph.D., is the President, Chief Executive Officer, Director of YM BioSciences Inc. Dr. Glover is the President and Chief Executive Officer of the
MISSISSAUGA, ON, Nov. 7, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced it would report updated results
Press Release Source: YM BioSciences Inc. On Tuesday March 30, 2010, 7:30 am EDT MISSISSAUGA, ON, March 30 /PRNewswire-FirstCall/
YM Biosciences Inc is a biopharmaceutical company engaged in the development of products for the treatment of cancer or cancer-related conditions.
Get the latest index performance and chart outlook for YM BIOSCIENCES INC ( YM.TO).
YM BIOSCIENCES INC (YM:CN) stock price & investing information. Find YM BIOSCIENCES INC historical stock quotes, key competitors, stock data, executives
YM BioSciences Announces Preclinical Results For JAK1/JAK2 Inhibitor CYT387 In Multiple Myeloma. Emergent Lowers FY 2011 Guidance;
YM BioSciences Inc. (YMI) announced on Monday that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab
YM BioSciences Reports Positive Updated Anemia Response Data For Its JAK1/ JAK2 Inhibitor CYT387 Disclosed At First Annual Florence
YM BIOSCIENCES INC. is a life sciences product development company focused 4: YM BioSciences Reports Operational and Financial Results for the First
YM BioSciences Inc. Bldg 11, 400-5045 Orbitor Dr Mississauga, ON L4W 4Y4 Tel : (905) 629-9761. Fax: (905) 629-4959. Contact Name James Smith. Industry
Free Online Library: YM BIOSCIENCES INC. - Directorate Change. by "PR Newswire UK Disclose"; News, opinion and commentary.
Research Reports for Day Traders: Alcoa, Ivanhoe Mines, General Electric, YM BioSciences, Procter & Gamble and Goldman Sachs
Synovis Life Technologies, YM BioSciences, Alexza Pharmaceuticals (Video Included Inside). Tue Dec 13 08:59. % of readers think this story is Fact. Add your
This report includes YM BioSciences, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets,
US:YMI - Get Stock quote detail for YM BioSciences Inc. Stock quotes include the latest US:YMI market price and fundamental investing data, price charts.
Stocks, YMI, YM BIOSCIENCES, stock, Amex Stock Exchange, YMI stock, YMI shares, stock trading.
8 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced the publication of Phase I results demonstrating that CYT997,
Get detailed financial information on YM BioSciences Inc. (USA) (NYSEAMEX: YMI) including real-time stock quotes, historical charts & financial news, all for
A positive anaemia response from a Phase I/II trial of YM BioSciences' lead project, CYT387, underscores the JAK inhibitor's competitive profile
About YM BioSciences Inc., YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients
Dividend YMI - Dividend Information for Ym Biosciences.
YM BioSciences (YMI) Reports Update from Phase I/II Data From Its YM BioSciences Inc. (NYSE: YMI) reported updated results from the
MISSISSAUGA, Ont. - YM BioSciences Inc. (TSX:YM) posted a $31.2-million annual loss for fiscal 2011 as the drug development company's
This one was brought to my attention by a buddy of mine. I know nothing about it other than it just got some news about approval of marketed a
YM BioSciences Inc. YMI (ASE). Help. Real-time prices for U.S.-listed stocks, including premarket and after hours, reflect trading through Nasdaq only.
What improvements would you like in Yahoo! Finance Message Boards? Please send us feedback. Message Boards Settings YM BioSciences
Incyte is already conducting patient and physician education (though that paves the way for YM Biosciences as well) and intends on hiring
Incyte (NAS: INCY) and Novartis' (NYS: NVS) ruxolitinib has a clear lead over YMÂ BioSciences' (ASE: YMI) CYT387, but that hasn't stopped.
MISSISSAUGA, ON, Nov. 7, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced it would report updated
Seite 95 der Diskussion 'YMI in this stock? oder YM Biosciences die Chance des Jahres!' vom 17.09.05 14:19 im w:o-Forum 'Biotech'
YM BioSciences Inc. - Product Pipeline Review - H2 2011 Summary Global Market Direct's pharmaceuticals report,
Thomas Allen, Counsel, Ym Biosciences Inc. of Ym Biosciences Inc.''s information - including email, business address, business phone, biography, title,
Financial Post YM Biosciences. YM Biosciences. Canada's most disappointing tech stocks. While some Canadian technology stocks are climbing fast, others are
YM BioSciences announced that the merger of Cytopia Limited into YM under a Scheme of Arrangement, has been concluded.
YM Biosciences has been working with YM Biosciences Australia (formerly Cytopia) on testing the JAK2 Inhibitor CYT387 in myelofibrosis patients. Enrollment
Ym Biosciences Inc on WN Network delivers the latest Videos and Editable pages for News & Events, including Entertainment, Music, Sports, Science and more,
Company profile for YM BioSciences. Includes latest key event, news and commentary, top selling products, worldwide prescription sales, sales by therapy area,
YM Biosciences, Inc. About Us YM BioSciences Inc., a Canadian company incorporated in 1994, principally develops cancer therapeutics. It partners with
YM BioSciences Inc. (YMI) Tuesday said its investigational compound CYT387 was granted orphan-designation by Committee for Orphan
Browse CNBC and partner stories, analysis, blogs and video catagorized by topic or author.
22, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported that, in view of the unusual market activity in the common
FE Investegate announcements from YM BioSciences Inc., YM BioSciences Initiates Patient Enrolment.
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 13, 2011. YM BioSciences Inc.
Ym Biosciences USA Inc company profile in Chesterbrook, PA. Our free company profile report for Ym Biosciences USA Inc includes business information such
YM BioSciences Inc. - Product Pipeline Review - Q4 2010 YM BioSciences Inc. - Product Pipeline Review - Q4 2010 Summary Global Market
YM BioSciences Inc. (YM) is a drug development company advancing a diverse portfolio of hematology and cancer-related products. The Company is advancing
YM Biosciences Inc, Wright Investors' Service Research Report: , published November 2011, pages 42, A textual analysis of the financial results for YM
Seite 96 der Diskussion 'YMI in this stock? oder YM Biosciences die Chance des Jahres!' vom 17.09.05 14:19 im w:o-Forum 'Biotech'
YM BioSciences Inc. said Friday it has named Nick Glover to the newly created role of president and chief operating officer.
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) announced on Monday that preliminary results of a Phase II study evaluating the safety and
Medical gadgets evolving. WNDU. Sat, 12/31/11 - 6:12 pm
YM BioSciences Inc. - ym. YM BioSciences Inc. ym go to snapshot add to favorites. post. see all posts, Overall Quality 2+, Overall Quality 3+, Overall Quality 4+
Facts and figures about YM BioSciences, taken from Freebase, the world's database.
Ym Biosciences YMI Stock News. Todays latest stock market news for Ym Biosciences from major news providers. New headlines for dow jones stocks and
Legal Name: YM BioSciences Inc. Operating Name: YM BioSciences Inc. Mailing Address 400-5045 Orbitor Dr Bldg 11. MISSISSAUGA
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2012 MISSISSAUGA, ON, Nov. 11, 2011 /CNW/ - YM .
Do not invest in Ym Biosciences Inc. (YMBA) stock before you read this free research report on the company.
Get SEC filings for YM Biosciences, Inc. (YMI), including Annual Report (10k) and Quarterly Report (10Q).
YM BIOSCIENCES INCSEC FILINGS. View all filings and insider trading for YM BIOSCIENCES INC.
Data Describes Nimotuzumab s Unique Binding Properties Resulting In Superior Side-Effect Profile Compared To Other EGFR-Targeting Drugs - MISSISSAUGA
Get company information on YM BioSciences Inc. and millions of other companies using the OneSource Free Directory.
YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today
AUSTRALIA - YM Biosciences Inc (YM) of Canada acquired the entire share capital of Cytopia Ltd (Cytopia), a Richmond-based biotechnology company, in a
Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Spicer J. Guy's Hospital, Department of Medical
Welcome to the company profile of YM BioSciences on LinkedIn. YM BioSciences Inc. is a life sciences product development company advancing a diverse
Penny stock company: YM Biosciences Inc., (YMI) is a biopharmaceutical company engaging in the production and distribution of drugs and
Fourth Quarter Revenue for YM BioSciences for its three months ended June 30th decreased by 55% to $227000. The industry
Canada-based drug maker YM BioSciences (TSE:YM) said on Tuesday that it has received orphan drug designation from the European
The oral JAK1/2 inhibitor CYT387 has emerged as Canada-based YM BioSciences' (TSX: YM) lead development project, having been
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011 - Significant and durable responses in
Get detailed financial information on YM BioSciences USA Inc. () including real- time stock quotes, historical charts & financial news, all for free!
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387PR
YM BioSciences Inc. (NYSE: YMI) is a drug development company advancing a portfolio of hematology and cancer-related products.
YM BioSciences YMI stock price, will YMI stock price go up? Is it a good time to buy YMI stock. Buy or sell YM BioSciences stock? Free YM BioSciences YMI
Stock analysis for YMI:US. Get stock price, historical stock charts & news for YM Biosciences Inc, in the Therapeutics industry.
MISSISSAUGA, Ont. - Changes to accounting rules helped drug developer YM BioSciences Inc. (TSX:YM) narrow its net loss to $900000 in its
YM BioSciences enrolls first patients in phase II CYT387 trial | CenterWatch News Online.
YM BioSciences Inc. (AMEX:YMI) and Threshold Pharmaceuticals, Inc. (NASDAQ :THLD) both took hits yesterday, but the likely outcome for
YM BioSciences Inc. (USA) (NYSEAMEX:YMI) witnessed volume of 3.62 million shares during last trade however it holds an average trading
About YM BioSciences YM BioSciences Inc. is a drug development company advancing three products: CYT387, a small molecule, dual
YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric
Sentiment about topic ym biosciences is 35% positive and 12% negative. Most positive related concepts to ym biosciences are story,columnist,drug.
YM BioSciences Inc., a Canadian company incorporated in 1994, principally develops cancer therapeutics. It partners with biotechnology and
AeroLEF by YM Biosciences Inc. is a top provider of Pharmaceuticals Drug Delivery. View AeroLEF product specs, pricing and contact YM Biosciences Inc. today.
Aegerion Announces Phase III 56-Week Data. YM BioSciences Announces Orphan Drug Designation.Below is a look at some of the headlines
Subtotal for Parent YM BioSciences: $40000. YM BioSciences Lobbying by Industry Itemized Lobbying Expenses for YM BioSciences
YM BioSciences (YMI) Not Aware of Any Reason Behind Unusual Stock Movement.
YM BioSciences Inc. (YM) is a drug development company advancing a diverse portfolio of hematology and cancer-related products.
YM BioSciences Inc., an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today
MISSISSAUGA, ON -- YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse
t.YM YM BioSciences Inc. YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011 12/12/2011 5:00:00 PM - Canada
Hoovers company profile of YM BioSciences USA Inc.. Find detailed business information such as key executives, financials and other corporate data on YM
YM BioSciences (AMEX:YMI; TSX:YM) has released results at the ASCO conference from a randomized Phase 2 gastric cancer study of its nimotuzumab drug
Why YM BioSciences Inc. will continue its uptrend?
Last December, YM Biosciences reported intriguing early data for CYT387, suggesting an unprecedented positive effect on anemia.
Tweets: YMI (YM BioSciences). Tweet This · chart. YMI (YM BioSciences - Msgs, Twts, Profile). Last: 1.61 -0.05 (-3.01%) · Vol: 204710 · Searches: 55 · Tweets: 2
Reminder: Pharmboy is available to chat with Members, comments are found below each post.YM BioSciences Inc. (AMEX: YMI) develops,
The "YM" in BioSciences might stand for "young and modern" as once the letters of YM magazine did. The firm was founded in 1994 to develop a variety of new
YM BioSciences Inc. reports preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of
YM Biosciences Inc is a biopharmaceutical company engaged in the development of products for the treatment of cancer or cancer-related
YMI - YM BioSciences Inc. (YMI) Stock Research Analysis - YM BioSciences Inc. ( YMI) Stock Research Analysis, Stock News, Stock Profile, Stock Summary,
MISSISSAUGA, ON, March 30 /PRNewswire-FirstCall/ - YM BioSciences Inc.
YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension.
YM BioSciences Inc.(AMEX:YMI, TSX:YM, AIM:YMBA), a company engaged in the acquisition,development and commercialization of oncology
CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July
Shares of drug development company YM BioSciences Inc. (YMI) (YM.TO) have fallen more than 50 percent from their one-year high and trade
YM BioSciences is a clinical development company that identifies and advances a YM BioSciences Reports Daiichi and Kuhnil Enrol First Patients in
YM BioSciences is a research client of Edison Investment Research Limited Last month's C$43m fund-raising should enable YM BioSciences to step up
YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM) today announced results of a collaboration with researchers at the University of Toronto for the
YM BioSciences Inc. (Ontario, Mississauga) YM BioSciences Inc. (Ontario, Mississauga). YM BioSciences Inc. 5045 Orbitor Drive Building 11, Suite 400
YM BioSciences has recruited first patients in a Phase II trial to evaluate CYT387 administered twice-daily (BID) for the treatment of
Companies are selecting final HER2/neu antibodies for clinics to treat lung, pancreatic, gastric, esophageal, head and neck cancer and glioma.
T.YM YM BioSciences Inc. YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011 12/12/2011 5:00:00 PM
YM BioSciences Inc. announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted
YM BioSciences, Inc. (USA) (AMEX:YMI). + Watch YMI. on My Watchlist. $1.67 0.01 (+0.60%). 1/11/2012 4:00 PM
I was reminded of the YM Bioscience (YM:TSX) story. YM BioSciences is a life sciences product development company with hematology and
Ym Bio Sciences Inc. $YMI Stream_3upwnce. Default_avatar_medium Ensui67 · Dec. 14 at 4:18AM · Ym Bio Sciences Inc. $YMI Stream_aney66k
The final product will be utilized by YM BioSciences and its licensees, Daiichi Sankyo in Japan, Kuhnil in South Korea, and Oncoscience AG in
Canada's YM BioSciences (YMI) is taking over Australia's Cytopia (CYTX), combining their cancer drug programs into a single pipeline in a $14
YM Biosciences Inc. microsite contains Pharmaceuticals BioPharma information on product specifications, white papers, and company information. Compare YM
Get detailed financial information on YM BioSciences Inc. (TSE:YM) including real-time stock quotes, historical charts & financial news, all for free!
The biotech is still at least three years from bringing a drug to market that can rival competitor Incyte's Jakafi.
News Release: - YM BIOSCIENCES INC - 2-3-2010 Ym Biosciences Reports Fiscal Third Quarter 2011 - YM BIOSCIENCES INC - 5-12-2011
Latest YM Biosciences Share Price and News. YM BioSciences is engaged in the licensing and commercialization of drug products and technologies from
Develops cancer therapeutics, mainly through partnerships and joint ventures. Lists products and their development phases, news, corporate and financial
YM Biosciences (YMI), a Canadian firm with Cuban connections, has seen its ups and downs, but since 28 June 2010, the company has been
Quickly understand and learn about YM BioSciences from your
Report for Alcoa (NYSE:AA), Ivanhoe Mines (NYSE:IVN), General Electric (NYSE: GE), YM BioSciences (AMEX:YMI), Procter & Gamble
YM Biosciences Reports Second Quarter 2009 Operational and Financial Results.
Adam Feuerstein, senior columnist, explains why YM Biosciences will be the biotech stock to watch in the coming week.
News for Medical Sales & Marketing professionals and Independent Sales Representatives: YM Biosciences Appoints Dr. Nick Glover as Chief
Register now for FREE live YM BioSciences Inc share prices, YM BioSciences Inc stock quotes, charts, trades and FREE YM BioSciences Inc company
Expectations were high leading up to a big cancer conference. Several companies are seeing their stocks sell off this week.
Everything relating to YM BioSciences: compilations of facts, news, background knowledge, product information and market trends can be found here in the form
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal YM BioSciences Inc. (NYSE: YMI) is a drug development company
YM BioSciences Inc (AMEX:YMI) is a Canadian company that seeks to treat cancer and cancer-related afflictions through the continued
Alexza Pharmaceuticals (ALXA) said today the U.S. Food and Drug Administration's psychopharmacologic advisory committee voted to
From Yahoo! Finance: YM BioSciences Inc. , today announced it would report updated results from its Phase I/II.
We are reiterating our BUY rating on YM BioSciences, Inc. (NYSE April 21, 2010, YM BioSciences, Inc. announced data for CYT387 in the
Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology
11, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011.
MISSISAUGA, ON, Oct. 19, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM) today announced that Catherine Mackey,
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported updated interim safety and efficacy results from the Phase I/II study of its
YM BioSciences Inc. financial and business news, updates, and information from The New York Times and other leading providers.
YM Biosciences is failing to convince many investors that it has the superior drug for treating myelofibrosis.
MISSISSAUGA, ON, May 11 /PRNewswire-FirstCall/ - YM BioSciences Inc.
Toronto based YM BioSciences Inc has made a $14.05 million recommended scrip offer for Australia's Cytopia Ltd, under which the pair will
Ym Biosciences Inc. Stock Price (YMI) Stock Quote and real time streaming Ym Biosciences - Stock Charts, - Company Information, News, Level 2 Data,
YM BioSciences Inc. (NYSE: YMI), today reported updated results from the ongoing Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the
YM Biosciences Inc (AMEX:YMI). Add to Watch List. Set Alert Latest YMI News | Press Releases. No recent news for YM Biosciences Inc.
YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumab; Phase II results presented at the 27th
The following information is taken from the YM BioSciences' "Corporate Presentation | Calendar Q3/2011," slide 31 titled "CYT387 Myelofibrosis Development
YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today reported
View the basic YMI stock chart on Yahoo! Finance. Change the date range, chart type and compare YM BioSciences, Inc. Ordinary S against other companies.
The Next Big Things In Biotech: YM Biosciences. TheStreetTV. Subscribe Subscribed Unsubscribe. Loading 2685 videos. Sign In or Sign Up
YM BIOSCIENCES INC COM NPV Toronto: YM.TO,TSE:YM technical analysis and research for investors, will it rise or fall?, come and read
YM Biosciences Inc operates in the Pharmaceutical preparations sector. YM BioSciences Inc. (YM) is a drug development company advancing a diverse
YM BioSciences Inc. is a drug development company advancing three products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2
YM BioSciences is an oncology-focused business developing compounds licensed from academia and acquired through takeovers. Its stock is
YM BioSciences' Upcoming CYT387 Catalyst May Be One To Watch YM BioSciences JAK Inhibitor CYT387 Shown Active in Multiple Myeloma. Yahoo
On December 17, 2010, YM BioSciences Inc. (AMEX: YMI; TSX:YM) (“YM BioSciences” or the “Company”) closed a $40 million public offering of 25000000
YM BioSciences Inc. is a drug development company advancing three clinical- stage products: CYT387, a small molecule, dual inhibitor of the
Results to be presented at the 52 nd American Society of Hematology Annual Meeting MISSISSAUGA, ON, Nov. 8 PRNewswire-FirstCall - YM BioSciences Inc.
YM BioSciences Inc. announces that it has enrolled the first patients in its multi- center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of
YM Biosciences stock Price (YMI), Stock Quotes and FREE real time streaming YM Biosciences Stock Charts, company fundamentals, Level 2 Data, Discussion
YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients
YM BioSciences reported updated Phase I/II data for its oral JAK1/JAK2 inhibitor CYT387 as a potential treatment for myelofibrosis (MF) in a 12
YM BioSciences Nimotuzumab Results Reported at SIOP Conference.
YM BioSciences, Inc. (NYSE AMEX: YMI, TSX: YM) is a life-sciences We are reiterating our BUY rating on YM BioSciences, Inc. (NYSE
Poster with broader update of trial results to be presented at ASCO - MISSISSAUGA, ON, May 18 - YM BioSciences Inc. (NYSE Amex YMI) (TSX YM), today
26, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of
Let's start with the data, YM Biosciences is again comparing Nimotuzumab to data collected during an already completed Phase II pilot study for
MISSISAUGA, ON, Oct. 19, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM) today announced that Catherine Mackey, Ph. D.,
Results 1 - 20 of 344 6-K, YM BIOSCIENCES INC, 12/12/11 (12/12/11). 6-K, YM BIOSCIENCES INC, 11/23/11 (11/22/11). 6-K, YM BIOSCIENCES INC, 11/14/11
Alexza Pharmaceuticals (ALXA) said today the U - ALXA,VRX,YMI.
MedGenesis and Cyplasin brought assets in, Canada and Australia are doing a do-sa-do (Topigen-Pharmaxis, YM-Cytopia), and Trillium Therapeutics signed
Instant ALOETTE COSMETICS INC versus YM BIOSCIENCES INC Stock Quotes. Analyze ALOETTE COSMETICS INC versus YM BIOSCIENCES INC Shares.
YM BioSciences Inc. Stock Message Board, YMI Stock Quote, YMI Stock Chart, YMI Stock News.
Collins Stewart Starts YM BioSciences (YMI) at Buy; Physicians are Collins Stewart initiates coverage on YM BioSciences (NYSE: YMI) with a
effect to the merger between YM BioSciences Inc. (“YM BioSciences”) and the Company at a meeting held on 12 January 2010. The Scheme is
Shared by: YM BIOSCIENCES INC Agreements Ym Biosciences Reports Interim Phase I/ii Data For Its Jak1/jak2 Inhibitor Cyt387 At Asco
Stock market news and stock research. Financial news, stock news and stock makrket update about the stocks, ETF and mutual funds listed on the NYSE, AMEX
Free Online Library: YM BIOSCIENCES INC. - Statement re YM BioSciences Raises US$40 MIllion. by "PR Newswire UK Disclose"; News, opinion and
menafn: YM BioSciences Inc's net loss narrowsCAD0.9m for first quarter fiscal 2012Nov 14, 2011 (M2 EQUITYBITES via COMTEX) --Drug
YM Biosciences, a cancer-focused product development company, has received approval to market nimotuzumab in Mexico. The company
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various
Scope - YM BioSciences Inc. - Brief company overview including business Assess the growth potential of YM BioSciences Inc. in its therapy areas of focus.
Ym Biosciences, Inc. (YMI) rated Buy with price target $6 by Roth Capital - GainersToday. See more Stock market recommendations, Upgrades
YM Biosciences has taken it on the chin after its ASCO presentation failed to impress investors. Its stock is now down about 21% from a high of
YM BioSciences, Inc. Class Action lawsuit news, YM BioSciences, Inc. class action lawsuit information, and links to YM BioSciences, Inc. news and stock price
Wells Fargo Starts YM BioSciences (YMI) at Outperform; Wells Fargo initiates coverage on YM BioSciences (NYSE: YMI) with a Outperform.
The Motley Fool - Playing catch-up in myelofibrosis.
YM Biosciences: News and Information for sales and marketing professionals and independent sales representatives in medical devices, pharmaceuticals and
YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING. - Find CNW Group articles.
As at April 30, the Company had 116467644 shares outstanding. About YM BioSciences YM BioSciences Inc. is a drug development company advancing.
Another tiny biotech, YM Biosciences (YMI ), trading on the Amex, may also have a winner: Tesmilifene for metastatic breast cancer. Now in Phase III trials,
Latest Ym Biosciences Share Price - Live YMBA share price quotes, charts, profile, RNS & company financials for YMBA.L.
YM BioSciences (Formerly York Medical, Inc.) 5045 Orbitor Drive Building 11, Suite 400. Mississauga Ontario L4W4Y4 Canada Phone: 905-629-9761 Fax:
YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM
MISSISAUGA, Canada I October 31, 2011 I YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) today announced that preliminary results of a
YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide.
Latest Pulse Events on YM BioSciences Inc. by Reni Benjamin of Rodman & Renshaw, Josh Schimmer of Leerink Swann & Company, Eben Tessari of
YM BioSciences is to acquire Canadian drug delivery company Delex Therapeutics and build its position in new drugs for cancer patients.
Shares of YM BioSciences Inc. (AMEX: YMI), a drug development company advancing a diverse portfolio of hematology and cancer-related
Name: